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ORIGINAL ARTICLE
Predictors of treatment response in young people at ultra-high
risk for psychosis who received long-chain omega-3 fatty acids
GP Amminger1, A Mechelli2, S Rice1, S-W Kim3, CM Klier4, RK McNamara5, M Berk6, PD McGorry1 and MR Schäfer1
Previous efforts in the prospective evaluation of individuals who experience attenuated psychotic symptoms have attempted to
isolate mechanisms underlying the onset of full-threshold psychotic illness. In contrast, there has been little research investigating
speciﬁc predictors of positive outcomes. In this study, we sought to determine biological and clinical factors associated with
treatment response, here indexed by functional improvement in a pre–post examination of a 12-week randomized controlled
intervention in individuals at ultra-high risk (UHR) for psychosis. Participants received either long-chain omega-3 (ω-3)
polyunsaturated fatty acids (PUFAs) or placebo. To allow the determination of factors speciﬁcally relevant to each intervention, and
to be able to contrast them, both treatment groups were investigated in parallel. Univariate linear regression analysis indicated that
higher levels of erythrocyte membrane α-linolenic acid (ALA; the parent fatty acid of the ω-3 family) and more severe negative
symptoms at baseline predicted subsequent functional improvement in the treatment group, whereas less severe positive
symptoms and lower functioning at baseline were predictive in the placebo group. A multivariate machine learning analysis, known
as Gaussian Process Classiﬁcation (GPC), conﬁrmed that baseline fatty acids predicted response to treatment in the ω-3 PUFA group
with high levels of sensitivity, speciﬁcity and accuracy. In addition, GPC revealed that baseline fatty acids were predictive in the
placebo group. In conclusion, our investigation indicates that UHR patients with higher levels of ALA may speciﬁcally beneﬁt from
ω-3 PUFA supplementation. In addition, multivariate machine learning analysis suggests that fatty acids could potentially be used
to inform prognostic evaluations and treatment decisions at the level of the individual. Notably, multiple statistical analyses were
conducted in a relatively small sample, limiting the conclusions that can be drawn from this ﬁrst-of-its-kind study. Additional studies
with larger samples are therefore needed to evaluate the generalizability of these ﬁndings.
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INTRODUCTION
Long-chain omega-3 (ω-3) polyunsaturated fatty acids (PUFAs)
have distinct and important bioactive properties compared with
the other groups of fatty acids.1,2 They reduce many risk factors
associated with disease, such as cardiovascular diseases,3
diabetes4 and some cancers.5 Omega-3 PUFAs are also of interest
in mental health, given their selective concentrations in synaptic
neuronal membranes,2 their regulatory role in the vascular and
immune functions affecting the central nervous system,2,6,7 as well
as evidence of the risks of insufﬁcient intakes.8,9
Evidence from controlled clinical trials suggests that ω-3 PUFAs
can have positive effects in a range of psychiatric conditions,10
including schizophrenia,11–13 and may be particularly effective in
the onset phase of psychosis. A 12-week supplementation with
long-chain ω-3 PUFAs (ﬁsh oil) signiﬁcantly reduced the risk of
progression from an at-risk state to a psychotic disorder during a
12-month period (5% for ω-3 PUFAs vs 28% for placebo), and led
to signiﬁcant symptomatic and functional improvements in young
people experiencing subthreshold psychotic symptoms.14 For
those in the active treatment group, pretreatment vs posttreat-
ment change in the erythrocyte membrane fatty acid ω-6 to ω-3
ratio correlated with functional improvement at 12 weeks, and
lower levels of nervonic acid, a long-chain monounsaturated ω-9
fatty acid important in the biosynthesis of myelin, appeared to be
a possible biomarker of risk of transition to psychosis.15 However,
while these results are encouraging, it is unclear whether there are
speciﬁc predictive factors associated with clinical improvement in
patients at ultra-high risk (UHR) for psychosis who receive ﬁsh oil.
The UHR criteria for psychosis aim to prospectively identify
individuals who are prodromal for schizophrenia or other
psychotic disorders.16 A recent meta-analysis of UHR studies
reported the rate of onset of a psychotic disorder in this group to
be 36% after 3 years.17 There are a number of factors that have
been associated with transition to psychosis in UHR individuals,
including age, severity of negative symptoms, subthreshold
positive symptoms, low psychosocial functioning, duration of
symptoms and illicit substance use.18–21 These factors can help
reﬁne diagnostic criteria to improve our ability to identify those
who are most at risk. However, studies in this ﬁeld of research
have typically focused on adverse outcomes; in particular,
transition to psychosis or poor functional outcome.17,22 Psycho-
social function is an important longitudinal outcome in individuals
at UHR and is independent of the presence of psychotic
symptoms or transition to psychosis.21,22 It is unclear whether
there are predictors in UHR individuals that are speciﬁcally
associated with positive outcomes (that is, functional
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improvement). To address this knowledge gap, we carried out a
secondary analysis of our randomized controlled trial.14 The
present study sought to determine if erythrocyte membrane fatty
acids and/or clinical factors at baseline predicted functional
improvement in young UHR individuals who did and did not
receive 12-week supplementation with ω-3 PUFAs.
MATERIALS AND METHODS
Sample
The present sample comprised 81 UHR individuals (27 males, 54 females;
mean age= 16.4, s.d. = 2.1 years) who were recruited as part of a double-
blind randomized controlled trial of ω-3 PUFAs vs placebo. This sample is
described in detail elsewhere.14 In brief, individuals were aged 13–25 years
and met the inclusion criteria proposed by Yung et al.16 for one or more of
the three operationally deﬁned groups of risk factors for psychosis:
attenuated positive psychotic symptoms (group 1); transient psychosis
(group 2); and genetic risk plus a signiﬁcant decrease in functioning (group
3). Study exclusion criteria were a history of a previous psychotic disorder
or manic episode (both treated or untreated), substance-induced psychotic
disorder, acute suicidal or aggressive behavior, a current DSM-IV diagnosis
of substance dependence (except cannabis dependence), any neurological
disorder, IQo70, structural brain changes apparent on magnetic
resonance imaging, previous treatment with an antipsychotic or mood-
stabilizing agent (41 week), having taken ω-3 supplements within 8 weeks
of being included in the trial, laboratory values 410% outside the normal
range for transaminases, thyroid hormones, C-reactive protein or bleeding
parameters, and any severe intercurrent illness that may have put the
person at risk or inﬂuenced the results of the trial or affected their ability to
take part in the trial.
All patients were consecutive admissions to a specialized psychosis
detection and treatment unit at the Department of Child and Adolescent
Psychiatry, Medical University Vienna, between May 2004 and May 2006.
The study was approved by the local ethics committee. All participants
provided written informed consent, including parental consent for those
less than 18 years of age. Patients were assessed within 1 week of their
initial presentation, and all UHR individuals were free of antipsychotic
medication.
Assessments
The Global Assessment of Functioning (GAF) score was used as the
measure of functioning. The GAF is an analog scale (0 through 100) to
subjectively rate the social, occupational and psychological functioning of
individuals, for example, how well or adaptively one is meeting various
problems in living.23 The Positive and Negative Syndrome Scale (PANSS) 24
was used to assess positive symptoms, negative symptoms and general
psychiatric symptoms. The Montgomery-Asberg Depression Rating Scale25
was used to examine depressive symptoms. Raters were experienced
clinicians who were trained in the administration of these instruments.
Inter-rater reliability estimates for all study instruments were excellent (all
intra-class correlation coefﬁcients 40.92). After randomization, partici-
pants received weekly assessments for 4 weeks, and then at 8 and
12 weeks (end of intervention) and subsequent follow-up at 6 and
12 months. For further detailed information on UHR criteria, randomiza-
tion, blinding and study measures, see Amminger et al.14
Analysis of erythrocyte membrane fatty acid composition
The erythrocyte fatty acid composition of the phosphatidylethanolamine
phospholipid fraction was quantiﬁed using capillary gas chromatography.
Phosphatidylethanolamine is the most common phospholipid on the inner
side of cell membranes in the brain. Values for the following classes of fatty
acids were obtained: saturated fatty acids (14:0, 16:0, 17:0, 18:0),
monounsaturated fatty acids (18:1ω-9, 20:1ω-9, 20:3ω-9, 22:1ω-9, 24:1ω-
9), trans fatty acids (18:1ω-7tr, 18:1ω-9tr) and PUFAs (18:2ω-6, 18:3ω-6,
20:3ω-6, 20:4ω-6, 22:2ω-6, 22:4ω-6, 18:3ω-3, 20:5ω-3, 22:5ω-3, 22:6ω-3). A
detailed description of the laboratory methods is provided elsewhere.26
More speciﬁcally, the current study investigated ω-3 PUFAs including α-
linolenic acid (ALA, 18:2ω-3), eicosapentaenoic acid (EPA, 20:5ω-3),
docosapentaenoic acid (DPA, 22:5ω-3) and docosahexaenoic acid (DHA,
22:6ω-3) due to their relevance to schizophrenia6,27 and psychosis9 and the
nature of the intervention in this study. In addition, we also examined key
ω-6 (linoleic acid, LA, 18:2ω-6; arachidonic acid, AA, 20:4ω-6) and ω-9
(nervonic acid, NA, 24:1ω-9) fatty acids that have been consistently
reported to be altered in people with schizophrenia.28–31
Treatment
The active treatment was a supplement of yellow gelatin 0.5 g capsules
containing concentrated marine ﬁsh oil. The daily dose of four capsules
provided 700mg of eicosapentaenoic acid (EPA, 20:5ω-3), 480mg of
docosahexaenoic acid (DHA, 22:6ω-3) and 7.6 mg of vitamin E. The daily
amount of other ω-3 fatty acids (18:3ω-3, 18:4ω-3, 20:4ω-3, 21:5ω-3, 22:5ω-
3) provided with the study medication was 220mg. The daily dose of
~ 1.2 g ω-3 PUFAs was based on trials in schizophrenia31,32 and ﬁrst-
episode psychosis.33 Coconut oil was chosen as placebo because it does
not contain polyunsaturated fatty acids and has no impact on ω-3 fatty
acid metabolism. Placebo capsules were carefully matched in appearance
and ﬂavor with the active treatment; they also contained the same amount
of vitamin E as the ω-3 capsules, and 1% ﬁsh oil to mimic taste. Adherence
to the study medication was monitored by pill count, self-report and
erythrocyte fatty acid quantiﬁcation. Antipsychotic medication or mood
stabilizers were not permitted. Patients could receive antidepressants for
moderate-to-severe depression (as indicated by a Montgomery-Asberg
Depression Rating Scale score of ⩾ 21) and benzodiazepines for anxiety,
agitation and/or insomnia. Existing prescriptions of psychiatric medications
were revaluated at baseline and continued if clinically indicated.
In addition to active/placebo treatment, all the patients were offered
nine sessions of needs-based psychological and psychosocial interventions
concurrently with the research follow-up interviews. These interventions
focused on presenting symptoms and pertinent issues, such as social
relationships and vocational and family issues. Additional appointments for
crisis management were offered to clients in accordance with the original
PACE (Personal Assistance and Crisis Evaluation) Clinic concept.34 Treating
clinicians also undertook a case management role providing assistance
with accommodation, education or employment and family education and
support.
Data analysis
The main objective of analysis was to determine predictors of pretreat-
ment (baseline) vs posttreatment (12–week) change in GAF score in UHR
patients who received ω-3 PUFAs or placebo. To eliminate treatment
effects and to allow the determination of factors speciﬁcally relevant to ω-3
supplementation, both treatment groups were investigated separately. For
individuals with missing data at the 12-week follow-up, the GAF change
score was calculated using last-observation-carried-forward approach. The
last-observation-carried-forward approach has low risk of bias in studies
with low drop-out rates. In the present study, 93% (37/40) of the ω-3 PUFA
group and 95% (38/40) of the placebo group completed the intervention
in accordance with the study protocol. A second type of missing data
occurred in this trial following transition to psychosis. Treatment with
antipsychotic medication was commenced in participants who made the
transition to psychosis, and no further data were collected after transition
(that is, for nine individuals). The outcome of interest—the values that
participants would have had if active treatment for psychosis had not been
initiated and the intervention and observation had continued—is thus
effectively counterfactual. In these circumstances, missingness is not
random and must be explicitly modeled.35 A conservative approach was
taken to model posttransition outcomes, as previously described
(Amminger et al.,14 p.149). It was assumed that functioning would have
been maintained at the transition levels if antipsychotic medications had
not been administered, but would not have further deteriorated.
Univariate analysis
Linear regression models were used to examine the relationship between a
baseline variable and change in GAF score from baseline to the end of
intervention (the dependent variable). Fatty acids relevant to schizo-
phrenia (that is, ALA, EPA, DPA, DHA, LA, AA, NA)27–30 and factors
previously shown to predict transition to psychosis (that is, age, negative
symptoms, positive symptoms, psychosocial functioning, duration of
symptoms, illicit substance use)18–21 were evaluated as independent
variables. Predictors with P-values o0.1 were then entered in a ﬁnal
prediction model. A sensitivity analysis was performed including only
those individuals who completed the intervention and made no transition
to psychosis (ω-3 group, n= 36; placebo group, n= 31). These tests were
carried out with the statistical package SPSS (version 20.0).
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Categorical analysis
Functional improvement was also investigated as a categorical variable,
using a ⩾ 15 point increase in GAF score as the cutoff to indicate
treatment response. This cutoff was based on the group median for the
baseline-to-12-week GAF score changes observed in the ω-3 PUFA
group. For comparisons of categorical variables, we calculated χ2
statistics, applying Fisher’s exact test when cell sizes were small.
Independent-samples t-tests were used to compare group differences in
baseline-to-12-week GAF score changes. Cohen’s d was calculated to
estimate the effect sizes of statistically signiﬁcant group differences. A
signiﬁcance level of 0.05 (two-tailed) was used for all statistical tests.
These tests were also carried out with the statistical package SPSS
(version 20.0).
Multivariate analysis
To complement the univariate analysis, we conducted a multivariate
analysis using a supervised machine learning technique known as
Gaussian Process Classiﬁcation (GPC) as implemented in the Pattern
Recognition for Neuroimaging Toolbox (PRoNTo; http://www.mlnl.cs.ucl.
ac.uk/pronto/). GPC is a Bayesian extension of standard logistic
regression that allows the classiﬁcation of individual observations into
distinct groups using the rules of probability.36 This technique
comprises a ‘training’ phase, in which well-characterized training data
are used to develop an algorithm, which captures the key differences
between groups, and a ‘testing’ phase in which the algorithm is used to
predict the group to which a new observation belongs to. A ‘leave-one-
out’ cross-validation method is used to estimate the accuracy, sensitivity
and speciﬁcity of the algorithm, providing an indication of its
generalizability. The statistical signiﬁcance of the accuracy can be
determined by permutation testing. A signiﬁcance level of 0.05 (two-
tailed) was used for all statistical tests. Except for the GPC analysis, tests
were carried out with the statistical package SPSS (version 20.0).
RESULTS
Of the 81 patients who were enrolled in the study, 80 (98.8%)
provided blood samples at baseline. Of those, 40 received ω-3
PUFAs and 40 received placebo for 12 weeks. Table 1 shows the
distribution of demographic and illness characteristics in these
treatment groups. No statistically signiﬁcant differences in these
variables were observed between the groups. By the end of the
intervention (12 weeks), one (2.5%) individual from the ω-3
PUFA group and eight (20.0%) individuals from the placebo
group made a transition to a threshold psychotic disorder
diagnosis (Fisher’s exact test: P=0.029). The mean change from
baseline to end point in GAF score was signiﬁcantly different
between the groups (ω-3 PUFA: M= 13.50, s.d. = 11.56; placebo:
M=7.50, s.d. = 13.63) (t =− 2.12, df = 78, P=0.037).
Univariate analysis
Linear regression analyses were undertaken with age, illicit
substance use, PANSS scores (that is, positive, negative),
duration of symptoms, GAF score and PUFAs (ALA, EPA, DPA,
DHA, LA, AA, NA) as independent factors and change in GAF
score pre–post intervention as the dependent variable. Within
the ω-3 group, higher scores on PANSS negative symptoms
(P= 0.034) and higher levels of erythrocyte membrane ALA
(P= 0.019) at baseline predicted functional improvement. In the
placebo group, lower PANSS positive scores (Po0.001) and
lower GAF scores at baseline (P= 0.007) were predictive of
functional improvement. In the ﬁnal regression models for the
treatment groups (Table 2), ALA and negative symptoms
explained 14% and 10% of the variance of functional change
in the ω-3 PUFA group, respectively, whereas positive symp-
toms and functioning explained 23% and 11% of the variance in
the placebo group, respectively. The results of the sensitivity
analysis, including participants without a transition to psychosis
who completed the intervention (ω-3 group, n=36; placebo
group, n=31), were consistent with the primary analysis (ω-3T
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group: negative symptoms, P=0.004; ALA, P= 0.047) (placebo
group: positive symptoms, Po0.001; GAF score, P= 0.006).
Concomitant medication use after randomization was low; that
is, antidepressants in 5 of 40 (12.2%) patients in the ω-3 group and
3 of 40 (7.5%) patients in the placebo group, and benzodiazepines
in 2 of 40 (4.9%) patients in the ω-3 group and 1 of 40 (2.5%)
patients in the placebo group. No statistically signiﬁcant associa-
tion was observed for receiving a concomitant medication and
functional improvement.
When the GAF score was dichotomized using a ⩾ 15 point
increase as the cutoff to indicate treatment response, 55.0% (22 of
40) of individuals in the ω-3 group and 30.0% (12 of 40) of
individuals in the placebo group achieved adequate functional
improvement (Pearson’s χ2: r= 5.115, df = 1, P=0.024). In the ω-3
group, the treatment response was associated with signiﬁcantly
higher scores of negative symptoms on the PANSS and
signiﬁcantly higher levels of erythrocyte membrane ALA
(Table 3). The effect size for the mean difference was large for
ALA (Cohen’s d=1.1) and medium for negative symptoms
(Cohen’s d= 0.7). In the placebo group, the treatment response
was associated with a signiﬁcantly lower PANSS positive symptom
score at baseline (Table 4). The effect size for the mean difference
in positive symptoms was also large (Cohen’s d= 0.9).
Multivariate analysis
Results indicated that fatty acids signiﬁcantly predicted response
to treatment (⩾15 point increase in GAF scores) in the ω-3 PUFA
group, with a sensitivity of 86.7%, a speciﬁcity of 86.7% and an
overall accuracy of 86.7% (Po0.001). In addition, fatty acids
signiﬁcantly predicted response to treatment (⩾15 point increase
of GAF scores) in the placebo group, with a sensitivity of 83.3%, a
speciﬁcity of 75.0% and an overall accuracy of 79.2% (Po0.001).
The relative contributions of the fatty acids to the above
predictions are displayed in Figure 1. It can be seen that the
contribution of the different fatty acids for predicting GAF change
appears to vary between the two groups, with some fatty acids
being more predictive in the ω-3 PUFA group and others being
more predictive in the placebo group. This pattern of results
suggests that some fatty acids may be predictive of response to ω-
3 treatment speciﬁcally, whereas others may be predictive of
clinical outcome in general. However, it should be noted that GPC
is a multivariate approach and as such it does not allow one to
make statistical inferences about the contribution of individual
fatty acids. In other words, all fatty acids informed prediction in
both groups to a greater or lesser extent, and the information on
the differential contribution of different fatty acids provided in
Figure 1 should be considered as descriptive only.
Table 2. Final regression of baseline predictors of functional improvement (change in GAF score) in individuals at ultra-high risk of psychosis, by
treatment group
Coefﬁcients B Standard error Beta T Signiﬁcance
Omega-3 group
ALA 75.8 30.8 0.35 2.46 0.019
Negative symptoms (PANSS) 0.68 0.31 0.32 2.20 0.034
Placebo group
Positive symptoms (PANSS) − 2.90 0.68 − 0.65 − 4.28 o0.001
GAF score − 39 0.16 − 0.37 − 2.44 0.020
Abbreviations: ALA, alpha-linolenic acid; GAF, Global Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale.
Table 3. Individuals at ultra-high risk of psychosis who received omega-3 fatty acids, by treatment response
Characteristic and measure Respondera (N= 22) Non-responder (N= 18) Difference between groups
N % N % r P
Substance abuse (lifetime) 8 36.4 4 22.2 0.94 0.33
Mean s.d. Mean s.d. t (df = 38) P
Age (years) 17.40 2.94 16.03 1.43 − 1.44 0.16
Duration of symptoms (months) 13.23 10.29 11.39 9.71 − 0.58 0.57
PANSS
Positive symptoms 15.18 3.72 14.83 3.07 − 0.32 0.75
Negative symptoms 15.59 5.83 12.22 4.25 − 2.05 0.048
GAF score 58.64 9.54 63.89 14.01 1.38 0.18
Erythrocyte fatty acids, % of total
α-Linolenic acid 0.21 0.06 0.16 0.03 − 3.78 0.001
Eicosapentaenoic acid 0.49 0.19 0.49 0.16 − 0.004 1.00
Docosapentaenoic acid 2.14 0.36 2.27 0.52 0.89 0.38
Docoshexaenoic acid 2.64 0.68 2.92 0.96 1.07 0.29
Linoleic acid 6.32 0.64 5.97 0.86 − 1.46 0.15
Arachidonic acid 15.42 1.98 16.24 2.47 1.16 0.25
Abbreviations: GAF, Global Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale. a⩾ 15 point increase on the Global Assessment of
Functioning scale was used to indicate response to treatment
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DISCUSSION
This is the ﬁrst study to investigate predictive factors associated
with clinical and functional improvement in UHR patients who
were treated with ω-3 PUFAs or placebo in addition to standard
clinical care without antipsychotic medication. A noteworthy
ﬁnding of this study is that higher baseline levels of ALA
predicted treatment response in the ω-3 PUFA group. ALA is the
shortest chain fatty acid in the ω-3 family, and this result is
consistent with the clinical observation that ω-3 PUFAs were
found effective in preventing transition to psychosis.14 Although
the past 20 years has seen an increasing interest and
remarkable knowledge gain regarding the roles of EPA and
DHA, the importance of ALA is still not fully elucidated.37 A
particular consideration is whether ALA has an essential
physiological role in its own right, or whether its major function
is to serve as a precursor of long-chain ω-3 PUFA synthesis (that
is, EPA, DPA, DHA). Currently, ALA is only known to have a
crucial metabolic function as a precursor.
In humans, the metabolic conversion of ALA to long-chain ω-
3 PUFAs, in particular DHA, is very limited and highly variable, at
least under physiological conditions.38,39 However, in situations
where the demand for long-chain ω-3 PUFAs is increased (for
example, during pregnancy and lactation), an upregulation of
the conversion from ALA to EPA and DHA may help to
compensate for this additional need.40 In schizophrenia,
pathological mechanisms, such as high oxidative stress41 or a
problem in the synthesis of long-chain fatty acids (for example,
a peroxisomal dysfunction or enzyme defect),42 contribute to
the depletion of EPA and DHA in cell membranes. This depletion
could stimulate physiological mechanisms, as is the case in
pregnant women, to upregulate the conversion rate of ALA to
long-chain ω-3 PUFAs. The view that ALA conversion is
upregulated to compensate for the loss of, or an increased
need for, long-chain ω-3 PUFAs in UHR patients is supported by
a comparison of the present study sample to 142 healthy
adolescents43 (Amminger et al., in preparation). This comparison
showed that UHR individuals have highly signiﬁcant deﬁcits for
erythrocyte membrane ALA (Cohen’s d=− 1.41);43 but not for
DPA or DHA. These observations are consistent with the notion
that an upregulation of ALA conversion may compensate for the
loss of long-chain ω-3 PUFAs during the at-risk/prodromal
phase (that is, resulting in low cell membrane ALA levels).
Accordingly, higher levels of ALA in UHR patients could indicate
a pathophysiological stage of illness where a person in the
onset phase of psychosis still has capacity to compensate for
the loss of long-chain ω-3 PUFAs, which may explain why higher
ALA levels in the current study were associated with better
outcome following EPA and DHA supplementation.
An important ﬁnding from the multivariate machine learning
analysis of this study is that fatty acids predicted response to
treatment in both treatment groups with high levels of
sensitivity, speciﬁcity and accuracy. Notably, the observed
values for the accuracy, that is, 87% in the ω-3 PUFA group
and 79% in the placebo group, were higher than those typically
found in neuroimaging studies of UHR individuals, which are in
the 65–80% range.44 The GPC analysis, therefore, corroborates
the result of the univariate analysis by showing that fatty acids
predicted response to treatment in the ω-3 PUFA group at the
level of the individual. In addition, the GPC analysis extends the
results of the univariate analysis by showing that fatty acids also
predicted treatment response in the placebo group. The
apparent inconsistency between the lack of signiﬁcant associa-
tion found in the univariate analysis and the high levels of
sensitivity, speciﬁcity and accuracy found in the multivariate
analysis, can be explained by the fact that the latter takes the
covariation between variables into account in addition to their
individual values. For example, it could be that individual fattyT
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acids have limited predictive power when considered separately
in the context of a univariate analysis, but have good predictive
power when considered jointly in the context of a multivariate
analysis. Overall, this pattern of results suggests that fatty acids
could potentially be used to inform prognostic evaluations and
treatment decisions at the level of the individual.
An interesting ﬁnding of this study is that more severe baseline
negative symptoms were associated with treatment response in
the ω-3 supplemented group. We have recently examined the
relationship between ω-3 PUFA (that is, ALA, EPA, DPA, DHA) levels
in erythrocyte membranes and measures of psychopathology
(PANSS positive, negative and general symptoms) in this UHR
cohort at baseline of the current trial. ALA, EPA and DHA did not
correlate with any symptom measure, whereas low levels of DPA
correlated with more severe negative symptoms.45 Therefore, the
present ﬁnding on negative symptoms is consistent with the view
that ω-3 PUFA metabolism is relevant to the negative symptom
syndrome of schizophrenia.46 This is also concordant with the
notion that oxidative damage to lipids is germane to the process
of neuroprogression and the expression of negative symptoms.47
However, it is also possible that in addition to the evidence
showing that negative symptoms and lipid biology may be
related, regression to the mean may be occurring here, since
those with severe negative symptoms at the start may also be
those who initially have poor functioning. Regression to the mean
may also contribute to the ﬁndings for positive symptoms and
GAF in the placebo group.
The ﬁndings of this study must be interpreted in view of its
limitations; most importantly, the relatively small sample size.
Small sample sizes can lead to spurious ﬁndings of signiﬁcant
results, and replication in larger samples is required. Furthermore,
the number of variables in the regression analysis, although they
were empirically selected, was relatively high, which increases the
chance of type I errors. However, the large effect size of the mean
difference for ALA in responders and non-responders in ω-3 PUFA-
treated individuals provides assurance of the validity of the
ﬁnding. The validity of the ﬁnding (that is, that ALA predicted
treatment response) in the ω-3 group is also supported by the
nature of the intervention. As mentioned above, a limitation of
GPC is that it does not allow one to make statistical inferences
about the contribution of individual fatty acids. Because all fatty
acids were included in this multivariate analysis, prediction of
clinical response in both the groups was informed by all of them
to a greater or lesser extent. Finally, the use of multiple
comparisons in post hoc analyses requires the ﬁndings to be seen
as exploratory rather than deﬁnitive. Strengths of the study
include the application of standardized assessment instruments;
that all assessments were conducted by experienced raters with
high inter-rater reliability; the study sample was drawn from a
representative cohort of UHR individuals assembled from a front-
line public psychiatric service with a geographically deﬁned
catchment area; and the robustness of key ﬁndings in the
sensitivity analysis.
Clinical characteristics alone are of limited predictive value and
there is a pressing need for further enhancement of predictive
models. Biological predictors of the course of illness and of
response to treatments are of enormous clinical value. In
conjunction with benign neuroprotective interventions, such
predictors have the potential to facilitate early targeted treatment
of biomarker-positive UHR individuals. In conclusion, the ﬁndings
in this study highlight the importance of lipid biology for the
treatment of subthreshold, attenuated forms of psychosis.
Additional studies with larger samples are needed to evaluate
the generalizability of these ﬁndings.
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